Abstract: A polymyxin B component or salts thereof, and a preparation and application thereof. The polymyxin B component includes six ?,?-diaminobutyric acids respectively at positions 1, 3-5 and 8-9, two threonine residues at positions 2 and 10, a phenylalanine residue at position 6 and a leucine residue at position 7 linked in sequence. The threonine residue at position 10 is linked to the ?,?-diaminobutyric acid at position 4 by an amido bond, and the ?,?-diaminobutyric acid at position 1 is linked to 6-methyloctyl-2-enoyl.

Abstract: The present invention relates to a method of cellulases enzymes production by Penicillium funiculosum MRJ-16 using minimum media components and/or low cost media components like cellulose or pretreated lignocellulosic biomass as carbon source and soya flour or defatted soya flour or de-oiled soya cake as nitrogen source. The present invention also provides a method for production of high titer of cellulases and hemicellulases enzymes using Penicillium funiculosum MRJ-16 using minimum media and/or low cost media components.

Abstract: A process for purifying a Streptococcus pyogenes GAS carbohydrate comprising a step of anionic exchange chromatography. The process provides a good yield of GAS carbohydrate. The saccharides of the invention have low levels of hyaluronic acid, protein and nucleic acid contamination.

Abstract: The present invention relates to a method for producing a botulinum toxin comprising: (a) treating a culture of a botulinum toxin-producing strain with acid to form a botulinum toxin-containing precipitate; (b) adding a buffer to the botulinum toxin-containing precipitate of step (a), followed by clarification by at least one method selected from the group consisting of depth filtration (DF), microfiltration (MF), ultrafiltration (UF), sterile filtration, membrane chromatography (MC) and centrifugation; (c) subjecting the botulinum toxin-containing solution of step (b) to UF diafiltration, ammonium sulfate precipitation or hydrochloric acid precipitation, and then diluting a retentate resulting from the UF diafiltration in a buffer or dissolving a precipitate resulting from the ammonium sulfate precipitation or hydrochloric acid precipitate in a buffer; and (d) subjecting the retentate dilution, ammonium sulfate precipitate solution or hydrochloric acid precipitate solution of step (c) to anion-exchange chrom

Abstract: The present invention provides simple, cost effective, rapid, and scalable at industrial scale and provide high purity and yield of Echinocandin-type compounds at low cost as compared to prior art. Moreover the process allows for the removal of impurities by using economical salt-adsorbent complex and provide highly purified Echinocandin type compounds which is highly improved in terms of purity and sufficient for further processing to obtain an active pharmaceutical ingredient such as, the antifungals caspogungin, anidulafungin, and micafungin.

Abstract: Disclosed is a method for the determination of the absence or presence of bacillus cereus enterotoxin in a protein sample via a western blot.

Abstract: Provided are a method of producing Clostridium botulinum toxin by using a media containing plant-derived components, and a method of producing Clostridium botulinum toxin by using a flexible closed container.

Abstract: This invention provides new cyclic lipopeptide antibiotic Locillomycin (Locillomycin-A, Locillomycin-B, Locillomycin-C) that display very strong antifungal, antibacterial, antivirus activities in a variety of contexts in vitro; methods of making and using the compounds, wherein Locillomycin-A, Locillomycin-B and Locillomycin-C are derived and purified from the culture of Bacillus subtilis Bs916.

Abstract: The present invention relates to a method of producing biosurfactants, such as surfactin, comprising culturing at least one biosurfactant-producing microbe in a liquid culture medium comprising vinasse as a carbon source. Methods of using the crude biosurfactant containing culture broth in tertiary oil recovery and as antibacterial compositions in tertiary oil recovery are also described. Methods of using the culture broth residue after isolation of the biosurfactants as fertilizer and compositions for this use are also described.

Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.

Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.

Abstract: A method for the manufacture of products by biotechnological methods in bacterial cell culture is disclosed as well as products obtained, the use of certain additives to the media used in the manufacture of said products in bacterial cell culture media, and the use of said additives in reducing the detrimental effects of radicals in the manufacture of the products, as well as aspects related to these invention embodiments. The manufacturing process or method comprises adding one or more radical scavenging and/or antioxidative additive preferably selected from the group consisting of sterically hindered nitroxyls, sterically hindered hydroxylamines, sterically hindered hydroxylamine salt compounds, sterically hindered amino compounds and sterically hindered N-hydrocarbyloxyamines, benzofuranone compounds, as obligatory component(s) to the medium used during biosynthesis.

Abstract: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic acid of the embodiments. These compositions find use in methods for controlling pests, especially plant pests.

Abstract: The present invention generally relates to a novel highly discriminating antibiotic, plantazolicin, a plantazolicin-like compound and to pharmaceutical compositions comprising the same. Also provided are methods for producing and using plantazolicin. Due to its bactericidal activity against Bacillus anthracis, plantazolicin and plantazolicin-like compounds can be used in methods for treating and/or preventing anthrax infections.

Abstract: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumor cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalized and inhibits secretion from said tumor cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.

Abstract: The present invention refers to a strain of Lactobacillus curvatus bacteria deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmBH (DSMZ) under thew accession number DSM 18775, as well as to compositions, cultures and food products comprising thereof. The strain of the invention is useful for preserving food products, especially under refrigerated conditions.

Abstract: The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.

Abstract: A method of producing a recombinant lipidated polypeptide in E. coli. The method includes providing an E. coli host cell adapted to express a recombinant lipidated polypeptide; and culturing the E. coli host cell in a minimal medium under conditions that allow expression of the polypeptide in lipidated form.

Abstract: The invention relates to proteins, notably SAP-2 and SAP-3, having an antibiotic action. The invention also relates to a method for purifying certain antimicrobial proteins, as well as to a use of said antimicrobial proteins for antibiotic therapy or to a use of cells which were transfected with a DNA which codes for the proteins provided for in the invention.

Abstract: The present invention relates to novel anti-TB cyclic peptides from Nonomuraea sp. MJM5123, a process for the production of the anti-Tuberculosis peptide and a pharmaceutical composition for the prevention and treatment of mycobacterial infection comprising the same. The composition of the present invention is highly active against replicating/non-replicating M. tuberculosis, including MDR and XDR strains, so that it can be effectively used as a therapeutic agent for tuberculosis.

Abstract: Provided is a bacteriocin that is capable of being easily mass-produced, has high antimicrobial activity even at low concentration, has a wide antimicrobial spectrum, and is less likely to produce resistant microorganisms. The bacteriocin has the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 in SEQUENCE LISTING, or has the same amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2 in SEQUENCE LISTING except that one or several amino acids are deleted, substituted, inserted and/or added, wherein the amino acid sequence provides antimicrobial activity and the isoelectric point is not less than 12.

Abstract: The present invention provides extracts of material fermented with Paenibacillus sp., preferably the one called here Paenibacillus elgii ourofinensis with antimicrobial activity and/or growth promoter in animals intended for slaughter for human consumption. The invention provides new peptides derived from the fractions of the fermentation of Paenibacillus elgii ourofinensis extract, said new peptides having antimicrobial activity and promoting the growth of organisms, for example, plants and animals. The invention is also related to the use of the extract of this new strain, Paenibacillus elgii ourofinensis, as a growth promoter and as an antimicrobial agent in the treatment and prophylaxis of animals intended for human consumption.

Abstract: The present invention concerns novel lantibiotic compounds, processes for the isolation and preparation thereof, pharmaceutical compositions containing the same, pharmaceutical acceptable salts thereof, and methods of use of the lantibiotics as antibacterial agents.

Abstract: Compositions and methods for conferring pesticidal activity, including against lepidopteran pests, to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated toxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:27 and 28, or the nucleotide sequence set forth in SEQ ID NO:3, 8, 13, and 18, as well as variants and fragments thereof.

Abstract: The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions.

Abstract: The present invention relates to a novel compound, 3-amino-2-hydroxy-4-phenylbutanoyl-valyl-isoleucine with structure showed below. The compound is prepared from fermentation culture Streptomyces parvus CGMCC No. 4027 and is active as inhibitor of aminopeptidase. It can be used for preparation of aminopeptidase inhibitor.

Abstract: The present invention relates to compositions and methods to identify novel bacteria and metabolites derived therefrom. More specifically, the invention describes a novel method to isolate bacteria producing metabolites of interest from environmental samples. Particularly, the invention discloses a method to select rare antibiotic producing bacteria. The invention can be used from any sample and allows the isolation of bacteria having e.g., pharmaceutical or agrochemical interest.

Abstract: The present invention pertains to a method to produce RTX-toxin Apxl by culturing Actinobacillus pleuropneumoniae bacteria in a liquid culturing medium that supports growth of the bacteria, to which medium a calcium salt is added to form calcium ions in the medium, wherein the culturing medium contains borogluconate to form a calcium borogluconate complex in the medium.

Abstract: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic acid of the embodiments. These compositions find use in methods for controlling pests, especially plant pests.

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

Abstract: The invention relates to a compound of the general structure (I), where R is a hydrogen atom (II) or an unsubstituted, monosubstituted or polysubstituted C1-C20-alkyl, wherein the alkyl is straight, branched, cyclic and/or partially unsaturated, or an unsubstituted, monosubstituted or polysubstituted phenyl group.

Abstract: Provided are: a novel compound having a structure different from that of existing drugs; a novel microorganism capable of producing the novel compound; and further; a novel compound effective to a multiple-drug-resistant bacterium. To provide a novel compound having a high therapeutic effect which can be expected to have a low hurdle for practical realization by selecting an intended compound from many candidate compounds based not only on an antibacterial activity but also on evaluation including a therapeutic effect, a cyclic peptide compound shown by the following formula (1) or a pharmaceutically allowable salt thereof and a microorganism with Accession No. NITE BP-870 or a microorganism mutated naturally or artificially therefrom are provided. (In the formula (1), R1 represents an acyl group having 7, 8, or 9 carbon atoms and optionally containing a substituent group; R2 represents a methyl group or a hydrogen atom; and R3 represents an ethyl group or a methyl group.

Abstract: The present invention provides novel antimicrobial bacteria strains and uses thereof to prepare novel antimicrobial agents. Also provided are the novel antimicrobial agents.

Abstract: The present invention discloses an improved process for the production of G-CSF in high yield via a high salt-induced increase in plasmid stability during the production phase.

Abstract: The current invention pertains to a method to produce RTX-toxins ApxI or ApxIII by culturing Actinobacillus pleuropneumoniae bacteria in a liquid culturing medium that supports growth of the bacteria, characterized in that air is passed through the medium, wherein the air has a carbon dioxide content above normal atmospheric level to increase RTX-toxin production during the production phase of the RTX-toxins.

Abstract: The present invention concerns a process for preparation of a biomass comprising one or a more plantaricins A, N or K in association with the lactic acid bacteria used for the preparation and uses thereof in order to stimulate the barrier function of intestinal cells or human epidermal keratinocytes.

Abstract: Granulysin peptides are small antimicrobial agents with potent activity. A pharmaceutical composition comprising granulysin peptides as an active agent is administered therapeutically to a patient for exfoliation, e.g. for the treatment of skin lesions.

Abstract: A method for the manufacture of products by biotechnological methods in bacterial cell culture is disclosed as well as products obtained, the use of certain additives to the media used in the manufacture of said products in bacterial cell culture media, and the use of said additives in reducing the detrimental effects of radicals in the manufacture of the products, as well as aspects related to these invention embodiments. The manufacturing process or method comprises adding one or more radical scavenging and/or antioxidative additive preferably selected from the group consisting of sterically hindered nitroxyls, sterically hindered hydroxylamines, sterically hindered hydroxylamine salt compounds, sterically hindered amino compounds and sterically hindered N-hydrocarbyloxyamines, benzofuranone compounds, as obligatory component(s) to the medium used during biosynthesis.

Abstract: Purified compounds of formula I are described. Compounds include all stereoisomeric forms and all tautomeric forms of the compounds of formula I and pharmaceutically acceptable salts and derivatives. Processes for the production of the antibacterial compounds by fermentation of the microorganism belonging to Streptomyces species (PM0626271/MTCC 5447) and to pharmaceutical compositions containing one or more of the novel compounds as active ingredient and their use in medicines for treatment and prevention of diseases caused by bacterial infections are described.

Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.

Abstract: Polynucleotides encoding the polypeptides involved in biosynthesis of FK 228 and those involved in synthesis of a novel FK228 analog, thailandepsin are disclosed herein. Also provided are methods of making FK228, thailandepsin and analogs of these molecules and methods of using these FK228 analogs. Chromobacterium and Burkholderia gene inactivation mutants are provided. Methods of forming a disulfide bond in a chemical are also disclosed.

Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.

Abstract: The invention is related to the process of fermentation with production strain Bacillus polymyxa for industrial production of antibiotic polymyxin B with yield from 1.8 to 2.8 g/l of filtrate of fermentation broth at temperature 28° C., pressure 40?70 kPa, aeration from 0.4 to 1 vvm, concentration of dissolved oxygen minimal 60%, maintenance of pH and optimal concentration of glucose and ammonium ions.

Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.

Abstract: The invention relates to novel conopeptides and/or novel uses of conopeptides. The conopeptides of the invention are analogs of ?-Conotoxin MII that are selective for ?6-containing nAChRs as described herein.

Abstract: The present invention provides isolated lantibiotics that inhibit. Gram negative and Gram positive microbes. The antibiotic includes an amino acid sequence, wherein the amino acid sequence of the compound and the amino acid sequence of SEQ ID NO:21 or SEQ ID NO:22 have at least 80% identity. The lantibiotics have the characteristic of inhibiting growth of a Gram negative microbe in conditions that do not damage the outer membrane of the Gram negative microbe. The present invention also provides methods for making and using the lantibiotics.

Abstract: This invention provides isolated and characterized secreted molecules from probiotic bacteria for use in compositions and methods for the treatment and/or prevention of infection by harmful pathogenic bacteria. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.

Abstract: The current invention pertains to a method to produce RTX-toxins ApxI or ApxIII by culturing Actinobacillus pleuropneumoniae bacteria in a liquid culturing medium that supports growth of the bacteria, characterised in that air is passed through the medium, wherein the air has a carbon dioxide content above normal atmospheric level to increase RTX-toxin production during the production phase of the RTX-toxins.

Abstract: The present invention pertains to a method to produce RTX-toxin Apxl by culturing Actinobacillus pleuropneumonica bacteria in a liquid culturing medium that supports growth of the bacteria, to which medium a calcium salt is added to form calcium ions in the medium, wherein the culturing medium contains borogluconate to form a calcium borogluconate complex in the medium.

Abstract: The present invention discloses an improved process for the production of G-CSF in high yield via a high salt-induced increase in plasmid stability during the production phase.